The meta-analysis using effect sizes showed that GLP1-RA therapy lead to similar rates of hospitalizations in patients with IBD compared to non-GLP1-RA therapy (HR: 0.91, 95% confidence interval [CI]: 0.71-1.17, I2 = 69%, P = 0.47) (Figure 3). This evidence concerns the gene GCG and inflammatory bowel disease.